462 related articles for article (PubMed ID: 25710470)
1. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Alexander T; Sarfert R; Klotsche J; Kühl AA; Rubbert-Roth A; Lorenz HM; Rech J; Hoyer BF; Cheng Q; Waka A; Taddeo A; Wiesener M; Schett G; Burmester GR; Radbruch A; Hiepe F; Voll RE
Ann Rheum Dis; 2015 Jul; 74(7):1474-8. PubMed ID: 25710470
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib in refractory ANCA-associated vasculitis: a new option?
Novikov P; Moiseev S; Bulanov N; Shchegoleva E
Ann Rheum Dis; 2016 Jan; 75(1):e9. PubMed ID: 26199397
[No Abstract] [Full Text] [Related]
3. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.
Alexander T; Cheng Q; Klotsche J; Khodadadi L; Waka A; Biesen R; Hoyer BF; Burmester GR; Radbruch A; Hiepe F
Eur J Immunol; 2018 Sep; 48(9):1573-1579. PubMed ID: 29979809
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Ichikawa HT; Conley T; Muchamuel T; Jiang J; Lee S; Owen T; Barnard J; Nevarez S; Goldman BI; Kirk CJ; Looney RJ; Anolik JH
Arthritis Rheum; 2012 Feb; 64(2):493-503. PubMed ID: 21905015
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus.
Quartuccio L; Rupolo M; Michieli M; De Vita S
Rheumatology (Oxford); 2014 Feb; 53(2):381-2. PubMed ID: 23962626
[No Abstract] [Full Text] [Related]
6. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Neubert K; Meister S; Moser K; Weisel F; Maseda D; Amann K; Wiethe C; Winkler TH; Kalden JR; Manz RA; Voll RE
Nat Med; 2008 Jul; 14(7):748-55. PubMed ID: 18542049
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
Sjöwall C; Hjorth M; Eriksson P
Lupus; 2017 Oct; 26(12):1333-1338. PubMed ID: 28162031
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib for refractory autoimmunity in pediatrics.
Khandelwal P; Davies SM; Grimley MS; Jordan MB; Curtis BR; Jodele S; Marsh R; Filipovich AH
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1654-9. PubMed ID: 24979732
[TBL] [Abstract][Full Text] [Related]
9. [Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man].
Voll R; Hiepe F
Z Rheumatol; 2009 Mar; 68(2):150-3. PubMed ID: 19224224
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient.
Wang Y; Zhou W; Zhang Z
Rheumatology (Oxford); 2015 Jan; 54(1):194-5. PubMed ID: 25288787
[No Abstract] [Full Text] [Related]
11. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
Gomez AM; Vrolix K; Martínez-Martínez P; Molenaar PC; Phernambucq M; van der Esch E; Duimel H; Verheyen F; Voll RE; Manz RA; De Baets MH; Losen M
J Immunol; 2011 Feb; 186(4):2503-13. PubMed ID: 21239719
[TBL] [Abstract][Full Text] [Related]
13. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
[TBL] [Abstract][Full Text] [Related]
14. Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study.
Walhelm T; Gunnarsson I; Heijke R; Leonard D; Trysberg E; Eriksson P; Sjöwall C
Front Immunol; 2021; 12():756941. PubMed ID: 34659263
[TBL] [Abstract][Full Text] [Related]
15. The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Lang VR; Mielenz D; Neubert K; Böhm C; Schett G; Jäck HM; Voll RE; Meister S
J Immunol; 2010 Nov; 185(9):5637-47. PubMed ID: 20921528
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
17. Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.
Rossi AP; Tremblay S; Castro-Rojas CM; Burg AA; Roskin KM; Gehman JM; Rike-Shields A; Alloway RR; Brailey P; Allman D; Hildeman DA; Woodle ES
Am J Transplant; 2023 Jun; 23(6):759-775. PubMed ID: 36871629
[TBL] [Abstract][Full Text] [Related]
18. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.
Ishii T; Tanaka Y; Kawakami A; Saito K; Ichinose K; Fujii H; Shirota Y; Shirai T; Fujita Y; Watanabe R; Chiu SW; Yamaguchi T; Harigae H
Mod Rheumatol; 2018 Nov; 28(6):986-992. PubMed ID: 29363990
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
